Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

(2021) Beatrice Arosio et al.   Frontiers in Behavioral Neuroscience

BDNF signaling in depression and antidepressant action

(2021) Eero Castrén et al.   BIOLOGICAL PSYCHIATRY

The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice

(2021) Agnieszka Pałucha-Poniewiera et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action

(2021) Pei-Yi Lin et al.   Cell Reports

Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine

(2021) Haitang Jiang et al.   Frontiers in Neuroscience

The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice

(2021) Anna Rafało-Ulińska et al.   BEHAVIOURAL BRAIN RESEARCH

A low-dose combination of ketamine and guanosine counteracts corticosterone-induced depressive-like behavior and hippocampal synaptic impairments via mTORC1 signaling

(2021) Anderson Camargo et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The influence of the duration of chronic unpredictable mild stress on the behavioural responses of C57BL/6J mice

(2020) Agnieszka Pałucha-Poniewiera et al.   BEHAVIOURAL PHARMACOLOGY

(2R,6R)-hydroxynorketamine exerts mGlu2receptor-dependent antidepressant actions

(2019) Panos Zanos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats

(2019) Agnieszka Pałucha-Poniewiera et al.   BEHAVIOURAL PHARMACOLOGY

Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine

(2019) Lijia Chang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism

(2019) Yukio Ago et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling

(2019) Atsuhiro Fujita et al.   PSYCHOPHARMACOLOGY

Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling

(2019) Yunfei Tan et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Esketamine is approved in Europe for treating resistant major depressive disorder

(2019) Elisabeth Mahase   BMJ-British Medical Journal

Mechanistic Target of Rapamycin–Independent Antidepressant Effects of ( R )-Ketamine in a Social Defeat Stress Model

(2018) Chun Yang et al.   BIOLOGICAL PSYCHIATRY

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

(2018) Panos Zanos et al.   PHARMACOLOGICAL REVIEWS

Antidepressant Potential of ( R )-Ketamine in Rodent Models: Comparison with ( S )-Ketamine

(2017) Kenichi Fukumoto et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Ketamine: 50 Years of Modulating the Mind

(2016) Linda Li et al.   Frontiers in Human Neuroscience

Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine

(2016) Chao Dong et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures

(2016) Ashley E. Lepack et al.   NEUROPHARMACOLOGY

Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats

(2016) Karolina Podkowa et al.   PSYCHOPHARMACOLOGY

Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model

(2016) H-L Sun et al.   Translational Psychiatry

Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor

(2015) Kinga Sałat et al.   NEUROPHARMACOLOGY

The translational study of apathy—an ecological approach

(2015) Flurin Cathomas et al.   Frontiers in Behavioral Neuroscience

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

(2015) C Yang et al.   Translational Psychiatry

BDNF Release Is Required for the Behavioral Actions of Ketamine

(2015) A. E. Lepack et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Acute Suppression of Spontaneous Neurotransmission Drives Synaptic Potentiation

(2013) E. Nosyreva et al.   JOURNAL OF NEUROSCIENCE

Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression

(2012) Hiroyuki Koike et al.   BEHAVIOURAL BRAIN RESEARCH

Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice

(2011) Maxime Cazorla et al.   JOURNAL OF CLINICAL INVESTIGATION

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

(2011) Anita E. Autry et al.   NATURE

CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy

(2011) Anita J. Bechtholt-Gompf et al.   PSYCHOPHARMACOLOGY

Measuring behavior in mice with chronic stress depression paradigm

(2009) Tatyana Strekalova et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY